About US
Contact us
-
Small group of branded drugs like Nexium, Copaxone make up huge part of Medicare spendIt's a good thing for Medicare that AstraZeneca's ($AZN)Nexiumhas gone generic and Teva's ($TEVA)Copaxoneis headed that way. That is because they are among about 10% of the drugs covered by Medicare w2015/5/4
-
GSK weighing scrapping investor payout to boost dividend insteadAnalysts are suggesting that GlaxoSmithKline ($GSK) is thinking hard about scrapping a plan to reward investors by paying them about £4 billion and instead use money from its deals with Novartis2015/5/4
-
Express Scripts: Fight against cancer drug prices 'much bigger' than hep CExpress Scripts ($ESRX) has been warning about a crackdown on cancer drug spending. Now, it's talking about how. The good news for pharma: It's not going to be a quick-hit, drama-filled operation lik2015/4/30
-
Ex-Sanofi exec Whitaker lands at Valeant in EVP roleSanofi's ($SNY) former North American pharma president, Anne Whitaker, has found yet another new place to call home. After departing from the French drug giant last year for the CEO's chair at Synta P2015/4/30
-
Mylan recalls injectable cancer meds, most produced for PfizerTop of mind for Mylan ($MYL) may be fending off an unsolicited $40 billion buyout offer from competitor Teva ($TEVA), but it still has to take care of business as usual. Right now that includes recall2015/4/29
-
FDA opens floodgates to generics of Bristol-Myers' Abilifyust hours after Bristol-Myers Squibb ($BMY) beat Wall Street expectations with earnings that got a goose from antipsychoticAbilify, the FDA opened the floodgates to generics of the blockbuster. The F2015/4/29
-
Rare-disease specialist Sobi entertains suitors for potential $3.5B-plus dealOrphan meds have been like catnip for drugmakers for several years, driving many an M&A deal. Now, Swedish Orphan Biovitrum might be next in line, at a price of more than $3.5 billion. The Stockh2015/4/28
-
FDA reviewers raise red flags for Amgen cancer vaccine ahead of AdCommWednesday's a big day for Amgen ($AMGN), whose dual-acting cancer vaccine/viral therapy is coming up for review by anFDApanel of experts. Agency reviewers have some serious questions about the drug's2015/4/28
-
Reckitt Benckiser makes out big time on the misery of U.S. flu sufferersThe fact that this flu season'svaccineswere not very effective was bad news for people hoping to avoid the condition but great news for the U.K.'sReckitt Benckiser Group, which racked up an impressive2015/4/27
-
Daiichi Sankyo gets EMA recommendation on clot busterJapan'sDaiichi Sankyogot some helpful news today as its works desperately to bring new revenue in the door ahead of next year's patent loss on its foundational product Benicar. The advisory group of t2015/4/27